Liontrust Discloses 5.03% Stake in MaxCyte
Liontrust Investment Partners disclosed a 5.03% beneficial stake in MaxCyte in a Schedule 13D filed Oct. 15, 2026. The filing details September sales followed by purchases on Oct. 14.
Liontrust Investment Partners disclosed a 5.03% beneficial stake in MaxCyte in a Schedule 13D filed Oct. 15, 2026. The filing details September sales followed by purchases on Oct. 14.